SBShilpa. P. Bhilegaonkar

Shilpa. P. Bhilegaonkar

*This is an algorithmically generated author record based on publicly available information.

Shilpa. P. Bhilegaonkar has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Formulation of Sertaconazole Nitrate-Based Pharmaceutical Systems for the Treatment of Onychomycosis

    by Shilpa. P. Bhilegaonkar, Purva. R. Laad, Hashweta Gawde, Amisha S. Raikar

    The study focused on developing transungual patches for the targeted treatment of onychomycosis, a common fungal infection of the nail. By incorporating Sertaconazole nitrate into patches using the Self-Microemulsifying Drug Delivery System (SMEDDS) technique, the aim was to overcome challenges related to drug penetration across the nail plate while enhancing solubility and permeability. Various patch formulations were prepared and extensively evaluated for key parameters such as thickness, weight variation, drug content, folding endurance, moisture content, moisture uptake, and in vitro drug release. The release data were analyzed using different kinetic models to understand the drug release mechanism. Selected formulations underwent accelerated stability testing per ICH guidelines, demonstrating stability under accelerated conditions. The study successfully addressed the challenges of transungual drug delivery, with the developed patches showing promising characteristics and stable release profiles. The application of kinetic models provided valuable insights, and the formulations passed stability testing, indicating their potential as effective and stable transungual drug delivery systems for the treatment of onychomycosis.

  • Open Access

    Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review

    by Amisha S. Raikar, Sushma Priya, Shilpa P. Bhilegaonkar, Sandesh N. Somnache, Deepak M. Kalaskar

    Cardiovascular diseases continue to be a major contributor to illness and death on a global scale, and the implementation of stents has given rise to a revolutionary transformation in the field of interventional cardiology. The thrombotic and restenosis complications associated with stent implantation pose ongoing challenges. In recent years, bioactive coatings have emerged as a promising strategy to enhance stent hemocompatibility and reduce thrombogenicity. This review article provides an overview of the surface engineering techniques employed to improve the hemocompatibility of stents and reduce thrombus formation. It explores the mechanisms underlying thrombosis and discusses the factors influencing platelet activation and fibrin formation on stent surfaces. Various bioactive coatings, including anticoagulant agents, antiplatelet agents, and surface modifications, are discussed in detail, highlighting their potential in reducing thrombogenicity. This article also highlights a multitude of surface modification techniques which can be harnessed to enhance stent hemocompatibility including plasma treatment, physical vapor deposition (PVD), chemical vapor deposition (CVD), and electrodeposition. These techniques offer precise control over surface properties such as roughness, charge, and composition. The ultimate goal is to reduce platelet adhesion, tailor wettability, or facilitate the controlled release of bioactive agents. Evaluation methods for assessing hemocompatibility and thrombogenicity are also reviewed, ranging from in vitro assays to animal models. Recent advances in the field, such as nanotechnology-based coatings and bioactive coatings with controlled drug release systems, are highlighted. Surface engineering of bioactive coatings holds great promise for enhancing the long-term outcomes of stent implantation by enhancing hemocompatibility and reducing thrombogenicity. Future research directions and potential clinical applications are discussed, underscoring the need for continued advancements in this field.


  • Open Access

    Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review

    by Amisha S. Raikar, Sushma Priya, Shilpa P. Bhilegaonkar, Sandesh N. N Somnache, Deepak M. Kalaskar

    Cardiovascular diseases continuing to be a major contributor to illness and death on a global scale and the implementation of stents has given rise to a revolutionary transformation in the field of interventional cardiology. The thrombotic and restenosis complications associated with stent implantation pose ongoing challenges. In recent years, bioactive coatings have emerged as a promising strategy to enhance stent hemocompatibility and reduce thrombogenicity. This review article provides an overview of the surface engineering techniques employed to improve the hemocompatibility of stents and reduce thrombus formation. It explores the mechanisms underlying thrombosis and discusses the factors influencing platelet activation and fibrin formation on stent surfaces. Various bioactive coatings, including anticoagulant agents, antiplatelet agents, and surface modifications, are discussed in detail, highlighting their potential in reducing thrombogenicity. Evaluation methods for assessing hemocompatibility and thrombogenicity are also reviewed, ranging from in vitro assays to animal models. Recent advances in the field, such as nanotechnology-based coatings and bioactive coatings with controlled drug release systems, are highlighted. Surface engineering of bioactive coatings holds great promise for enhancing the long-term outcomes of stent implantation by enhancing hemocompatibility and reducing thrombogenicity. Future research directions and potential clinical applications are discussed, underscoring the need for continued advancements in this field.


  • Formulation and Evaluation of Bilayer Gastric Mucoadhesive Patch of Captopril

    by Shilpa P. Bhilegaonkar, Sharayu G. Volvoikar, Anisha G. Naik

    The goal of the present investigation was to design and evaluate bilayered gastro-retentive mucoadhesive patches of Captopril. Captopril is a potent ACE inhibitor, widely used in the treatment of hypertension. Given orally, Captopril is absorbed rapidly and has a bioavailability of 75%, peak plasma concentrations occur within an hour and is cleared rapidly with a short biological half-life of about 2–3 hours. The drug is freely soluble in water and has site specific absorption from GIT. The drug is unstable in alkaline pH of intestine, where as stable in acidic pH and specifically absorbed from stomach. All these factors may lead to fluctuations in bioavailability, thus the present research proposes a formulation to overcome the above mentioned problems, by formulating an oral bilayered gastric mucoadhesive patch of Captopril. The bilayered patch consists of an immediate release layer made up of HPMC E15, a mucoadhesive layer composed of polymers: Chitosan and HPMC K15. The patches were evaluated for their thickness, weight variation, folding endurance, swelling behavior, unfolding study, mucoadhesive strength and time. In-vitro drug release studies were conducted for the Captopril loaded patches in 0.1N HCl and a maximum release was shown by formulation F8 (96.73%) in 12 hours. The data of invitro drug release was fitted into kinetic models (Zero order, First order, Higuchi and Korsmeyer-Peppas models) to explain the release kinetics and mechanism of release, which inturn was found to follow zero order kinetics with non-fickian diffusion. The prepared patch was found to be stable for three months at accelerated storage conditions according to ICH.